0000947871-26-000462.txt : 20260423 0000947871-26-000462.hdr.sgml : 20260423 20260423185038 ACCESSION NUMBER: 0000947871-26-000462 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260421 FILED AS OF DATE: 20260423 DATE AS OF CHANGE: 20260423 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bonita David P CENTRAL INDEX KEY: 0001572451 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39527 FILM NUMBER: 26890063 MAIL ADDRESS: STREET 1: C/O ORBIMED ADVISORS LLC STREET 2: 601 LEXINGTON AVENUE, 54TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Prelude Therapeutics Inc CENTRAL INDEX KEY: 0001678660 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 811384762 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 175 INNOVATION BOULEVARD CITY: WILMINGTON STATE: DE ZIP: 19805 BUSINESS PHONE: (302) 467-1280 MAIL ADDRESS: STREET 1: 175 INNOVATION BOULEVARD CITY: WILMINGTON STATE: DE ZIP: 19805 FORMER COMPANY: FORMER CONFORMED NAME: Prelude Therapeutics Inc. DATE OF NAME CHANGE: 20160630 4 1 ownership.xml X0609 4 2026-04-21 0 0001678660 Prelude Therapeutics Inc PRLD 0001572451 Bonita David P false C/O PRELUDE THERAPEUTICS INC. 175 INNOVATION BOULEVARD WILMINGTON DE 19805 1 0 1 0 0 Common Stock 2026-04-21 4 P 0 1689189 4.44 A 11808945 I See footnotes Common Stock 2026-04-21 4 P 0 1126126 4.44 A 1126126 I See footnotes Common Stock 526300 I See footnotes These securities were purchased in an underwritten public offering. These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI. These securities are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM. These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund. Each of the Reporting Person, OrbiMed Advisors, GP VI, OrbiMed Capital and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. /s/ David P. Bonita 2026-04-23